TGTX
Tg Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$61.18Close
$9.5BMarket cap
$26.94 – $61.1852-week range
Nov 2, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 96 · stronger than 96% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Accumulation up-day volume 1.7× down-day volume over 50 sessions
Cautions
- Earnings shrinking EPS −71% year on year
- Results soon Nov 2, 2026, in 1 day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 12.9%
price change
1mo
up 9.7%
price change
12-month return
up 80%
market up 11% ·
its own up 70%
F-score
5 / 9
Mixed
Altman Z
13.81
Low risk
P/E
21.2×
price / earnings
PEG
0.01
P/E / EPS growth
P/B
14.7×
price / book
Earnings yield
up 1.3%
EBIT / enterprise value
Cheaper than
21%
of the market · expensive
Revenue growth
up 87%
year on year
EPS growth
down 71%
latest quarter · -369 pts
Sales growth
up 70%
latest quarter · +1 pts
ROE
up 103%
return on equity
Free cash margin
down 4%
-$25.0M FCF
D/E
0.38
long-term debt / equity
Net debt / EBITDA
1.3×
Interest cover
—EBIT / interest
Piotroski tests
- operating cash flow is negative
- profits not fully backed by cash
- short-term liquidity weakened
- gross margin narrowed
- profitable on its assets
- profitability improving
- reduced long-term debt
- no new shares issued
- assets working harder
Trade setup
ATR%
3.8%
$2.33 a day · 2×ATR $56.51
RS
96 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.6×
vs 50-day average
Up/down volume
1.68
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Profit not backed by cash Reported profit of $447.2M came with -$24.8M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
- Gross margin narrowing Gross margin fell from 88.3% to 83.7%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 3, 2026
Last shock
Aug 3, 2026-11% in one session2.4× volumeon results+33% since
Financials
- Gross 84%
- Net 73%
- Free cash -4%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $152,000 | $6.7M | $2.8M | $233.7M | $329.0M | $616.3M |
| Gross margin | — | 88% | 90% | 94% | 88% | 84% |
| Operating income | -$273.6M | -$344.8M | -$218.3M | $20.6M | $41.9M | $123.3M |
| Net income | -$279.4M | -$348.1M | -$198.3M | $12.7M | $23.4M | $447.2M |
| Net margin | -183803% | -5204% | -7120% | 5% | 7% | 73% |
| Earnings per share | -$2.42 | -$2.63 | -$1.46 | $0.09 | $0.15 | $2.77 |
| Free cash flow | -$214.9M | -$296.0M | -$176.2M | -$31.4M | -$40.6M | -$25.0M |
| Free cash margin | -141358% | -4426% | -6326% | -13% | -12% | -4% |
| Cash | $553.4M | $298.9M | $102.3M | $92.9M | $179.9M | $79.1M |
| Long-term debt | $7.7M | $66.8M | $71.1M | $100.1M | $244.4M | $245.6M |
| Shareholders' equity | $519.4M | $237.2M | $58.6M | $160.5M | $222.4M | $648.0M |
| Shares outstanding | 140.58m | 143.25m | 146.39m | 151.42m | 155.84m | 155.31m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 3, 2026 | Results ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| Jun 3, 2026 | Other events ↗ |
| May 27, 2026 | Other events ↗ |
| May 6, 2026 | Results ↗ |
| Mar 20, 2026 | Material agreement · New obligation ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 13, 2026 | Regulation FD ↗ |
| Nov 3, 2025 | Results ↗ |
| Aug 4, 2025 | Results ↗ |
| Jun 13, 2025 | Shareholder vote ↗ |
| May 5, 2025 | Results ↗ |